| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Arcutis Biotherapeutics, Inc. (ARQT) has 13 insiders with recent SEC Form 4 filings, including 2 buys and 8 sells. ARQT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 740.5K | $19.74M | - | |
| Other | 150.2K | $4.00M | - | |
| Other | 127.6K | $3.40M | - | |
| Other | 120.2K | $3.21M | - | |
| CFO | 86.0K | $2.29M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 2, 2024 | Moore Matthew Richard | SVP And Chief Business Officer | Sell | 4,681 | $8.74 | $40,901.64 | -3.1% | +17.1% | +77.2% | |
| Mar 4, 2024 | Moore Matthew Richard | SVP And Chief Business Officer | Sell | 3,468 | $11.12 | $38,568.32 | -2.3% | -25.4% | +22.4% | |
| Mar 4, 2024 | Heron Patrick J87 | Director | Buy | 21,052 | $9.50 | $199,994.00 | +0.2% | -25.4% | +22.4% | |
| Mar 4, 2024 | Matsuda Masaru51 | See Remark | Sell | 3,760 | $11.12 | $41,815.71 | -1.9% | -25.4% | +22.4% | |
| Mar 4, 2024 | Burnett Patrick | See Remarks | Sell | 4,782 | $11.12 | $53,181.58 | -1.7% | -25.4% | +22.4% | |
| Mar 4, 2024 | Watanabe Todd Franklin65 | See Remarks | Sell | 14,903 | $11.12 | $165,739.24 | -1.7% | -25.4% | +22.4% | |
| Feb 28, 2024 | Watanabe Todd Franklin65 | See Remarks | Sell | 2,465 | $10.60 | $26,129.00 | -0.3% | -14.7% | +23.0% | |
| Jan 2, 2024 | Burnett Patrick | See Remarks | Sell | 1,325 | $3.54 | $4,691.56 | -2.3% | +182.2% | +324.5% | |
| Nov 21, 2023 | Matsuda Masaru51 | See Remark | Sell | 1,850 | $1.98 | $3,661.15 | -3.8% | +401.6% | +438.6% | |
| Oct 24, 2023 | Frazier Life Sciences Viii, L.P. | 10% Owner | Buy | 80,000 | $2.50 | $200,000.00 | +0.9% | +48.1% | +249.4% |